Nutraceutical major British Biologicals with its two nutritional products Promaxe and Nutrizen from its Criticare Division prescribed to address the conditions like burns, post surgery and multiple trauma is now working to consolidate its presence in the market.
Promaxe and Nutrizen require adequate nutrient and metabolic support to control pain and uneasiness. The state of stress on the body expends large amounts of energy to heal inflammation, support immune function and tissue repair. Comprehending the needs for protein rich supplements providing high calories for trauma patients to recover from any major injury like wound, burns, infections and cancer, British Biologicals research team came out with the two products which are the revenue generators of the future.
Dr Anand Alladi, Sr. Consultant, Dept. of Paediatric surgery and Paediatric Urology Apollo Hospital, Bangalore and Faculty of Bangalore Medical College mentioned that patients requiring major surgery for head-neck, and abdominal cancer apart from larynx, pharynx or oesophageal resection,gastrectomy, pancreato duodenectomy often exhibit nutritional depletion before surgery and run a higher risk of developing septic complications. Postoperatively, oral intake is often delayed due to swelling, obstruction, impaired gastric emptying or paralytic ileus, making it difficult to meet nutritional requirements. In these patients surgeons consider nutritional support to reduce morbidity and immune-modulating formulae that appear to be especially efficacious, he stated.
While Promaxe is enriched with glutamine to meet the needs of patients including burns, infections like HIV and cancer, Nutrizen is a nutritional supplement that provides adequate calories, proteins, vitamins and zinc needed for rapid wound healing. It is indicated in patients with post surgical healing of wounds, diabetics suffering from wound infection, minor wounds or cuts after an accident and allergy due to nutritional deficiencies, stated VS Reddy, chairman and managing director, British Biologicals.
The two new launches take the total number of products of the company to 12. “From our range which cover general health with ‘B Protein’, women’s health with ‘Pro PL and ‘Meno Pro’, child health with ‘Kids Pro’ diabetes with ‘D Pro’, cholesterol management with Colred, Liver with ‘Hepa Pro’, weight management with Medislim and Pulmonary distress with Pulmocare, and Pulmoplus, we have found that Hepa pro, Pulmocare, and Pulmoplus are the fastest growing in the range. In fact in fiscal 2010-11, B Protein and D Protein chipped in 65 per cent to the company’s revenues of Rs.400 crore registering a growth rate of 22 per cent over the last 36 months,” he added.
Further, the company which is a dedicated nutraceutical major with a leadership status present in a market valued at Rs.400 crore, has slated a Rs.150 crore investment for a Greenfield production plant being constructed according to US FDA regulations at Jigani Industrial Area, Bangalore on a four acre lot. The plant would span over an area of 1.5 lakh sq.ft, out of which 25,000 sq. ft would be a dedicated area for R&D and quality control labs, said Reddy.
Future areas of focus would be Neurology and Orthopaedic segments which require a nutritional supplement to address the systemic inflammatory response syndrome.